On April 1, 2021, Xiong, Shili; Wang, Nan; Liu, Chao; Shen, Huaxing; Qu, Zengqiang; Zhu, Lijun; Bai, Xiaosong; Hu, Hong-gang; Cong, Wei; Zhao, Liang published an article.SDS of cas: 98946-18-0 The title of the article was Design, synthesis, and anti-tumor activities of novel Brevinin-1BYa peptidomimetics. And the article contained the following:
Brevinin-1BYa is an amphibian skin-derived peptide that exhibits promising anti-microbial activity against gram-pos. and -neg. bacteria. However, the anti-tumor activity of Brevinin-1BYa remains unclear, and, more importantly, its therapeutic application is limited owing to its poor protease and reduction stability. In this study, a series of novel Brevinin-1BYa derivatives, including O-linked N-acetyl-glucosamine glyclopeptides and disulfide bond mimetics, were designed and synthesized. Addnl., their anti-tumor activity against human prostate cancer cell line C4-2B, human NSCLC cell line A549 (adenocarcinoma), and human hepatoma cells line HuH-7 was investigated. Among these, the thioether bridge substituted peptidomimetic Brevinin-1BYa-3 displayed improved reduction stability, more stable secondary structure, greater protease stability, and increased anti-tumor activity compared with the original peptide, rendering it a promising leading compound for drug development, particularly for applications against malignant tumors. The experimental process involved the reaction of tert-Butyl trichloroacetimidate(cas: 98946-18-0).SDS of cas: 98946-18-0
The Article related to cyclic peptide synthesis glycopeptide antitumor structure activity drug design, homoserine bromination solid phase synthesis peptide coupling oxidative cyclization, peptidomimetic click chem azide alkyne cycloaddition copper catalyst lactamization, secondary structure enzymic stability peptide folding hemolysis, anti-tumor activity, brevinin-1bya and other aspects.SDS of cas: 98946-18-0
Referemce:
Chloride – Wikipedia,
Chlorides – an overview | ScienceDirect Topics